375Hoskins JM, Goldberg RM, Qu P, et al. UGT1A1*28 genotype and irinotecan-induced neutrope-
nia: dose matters. J Natl Cancer Inst. 2007;99:1290–5.
Hossain M, Luo Y, Sun Z, et al. X-ray enabled detection and eradication of circulating tumor cells
with nanoparticles. Biosens Bioelectron. 2012;38:348–54.
Huang RS, Duan S, Bleibel WK, et al. A genome-wide approach to identify genetic variants that
contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A. 2007;104:9758–63.
Inoges S, Rodriguez-Calvillo M, Zabalegui N, et al. Clinical benefi t associated with idiotypic vac-
cination in patients with follicular lymphoma. J Natl Cancer Inst. 2006;98:1292–301.
Iwanami A, Gini B, Zanca C, et al. PML mediates glioblastoma resistance to mammalian target of
rapamycin (mTOR)-targeted therapies. Proc Natl Acad Sci U S A. 2013;110:4339–44.
Jain KK. Role of oncoproteomics in the personalized management of cancer. Expert Rev
Proteomics. 2004;1:49–55.
Jain KK. Role of nanobiotechnology in developing personalized medicine for cancer. TCRT.
2005;4:645–50.
Jain KK. Textbook of hyperbaric medicine. 5th ed. Göttingen: Hogrefe & Huber; 2009.
Jain KK. Personalized cancer vaccines. Expert Opin Biol Ther. 2010;12:1637–47.
Jain KK. Applications of biotechnology in oncology. New York: Springer; 2014.
Jain KK. Molecular diagnostics: technologies, markets and companies. Basel: Jain Pharma
Biotech; 2015.
Janikashvili N, Larmonier N, Katsanis E. Personalized dendritic cell-based tumor immunotherapy.
Immunotherapy. 2010;2:57–68.
Jeon JS, Bersini S, Gilardi M, et al. Human 3D vascularized organotypic microfl uidic assays to
study breast cancer cell extravasation. Proc Natl Acad Sci U S A. 2015;112:214–9. doi: 10.1073/
pnas.1417115112.
Jha P, Suri V, Jain A, et al. O6-methylguanine DNA methyltransferase gene promoter methylation
status in gliomas and its correlation with other molecular alterations: fi rst Indian report with
review of challenges for use in customized treatment. Neurosurgery. 2010;67:1681–91.
Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver
cancer. NEJM. 2009;361:1437–47.
Ju YS, Lee WC, Shin JY, et al. Fusion of KIF5B and RET transforming gene in lung adenocarci-
noma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012;22:
436–45.
Juhász C, Muzik O, Lu X, et al. Quantifi cation of tryptophan transport and metabolism in lung
tumors using PET. J Nucl Med. 2009;50:356–63.
Jung SY, Rosenzweig M, Sereika SM, et al. Factors associated with mortality after breast cancer
metastasis. Cancer Causes Control. 2012;23:103–12.
Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and signifi cance across 12 major
cancer types. Nature. 2013;502:333–9.
Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefi t from cetuximab in
advanced colorectal cancer. N Engl J Med. 2008;359:1757–65.
Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in
non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U
S A. 2011;108:7535–40.
Kim Y, Wu Q, Hamerlik P, et al. Aptamer identifi cation of brain tumor-initiating cells. Cancer Res.
2013;73:4923–36.
Kim HK, Park WC, Lee KM, et al. Targeted next-generation sequencing at copy-number break-
points for personalized analysis of rearranged ends in solid tumors. PLoS One. 2014a;
9(6):e100089.
Kim JH, Sohn BH, Lee HS, et al. Genomic predictors for recurrence patterns of hepatocellular
carcinoma: model derivation and validation. PLoS Med. 2014b;11(12):e1001770.
Kimura H, Kasahara K, Kawaishi M, et al. Detection of epidermal growth factor receptor muta-
tions in serum as a predictor of the response to gefi tinib in patients with non-small-cell lung
cancer. Clin Cancer Res. 2006;12:3915–21.
References